The Tool Desk
Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →Federal actions in 2025 disrupted NIH grant review and funding, while a House Oversight Democratic staff report identifies a canceled HIV vaccine grant and delayed HIV prevention funding in Los Angeles County. These examples show real risks to research and services, but they do not mean every HIV grant was terminated or establish that the disruptions caused a measured rise in HIV infections.
How the 2025 NIH review pause disrupted grants
The U.S. Government Accountability Office (GAO) documented an NIH-wide interruption in grant review. After executive orders issued January 20–21, 2025, including one directing agencies to terminate equity-related grants, the Department of Health and Human Services (HHS) issued a January 21 memorandum halting publication of grant-review meeting notices in the Federal Register while it reviewed the notices.
As an Amazon Associate I earn from qualifying purchases.
GAO found that NIH grant-review notices did not appear from January 22 through March 3, 2025. NIH advisory council meetings resumed March 18, and rescheduled or newly scheduled peer-review groups resumed March 24. Because NIH reviews require advance notices and two levels of peer review, GAO concluded that the publication pause temporarily prevented NIH from reviewing and subsequently awarding grants.
What GAO found about NIH-wide funding
GAO says NIH terminated more than 1,800 grants between February and June 2025. That is a count across NIH, not a count of HIV grants. In a separate comparison, GAO found NIH obligations for February through June of fiscal year (FY) 2025 were almost $8 billion lower than obligations for the same months of FY 2024; that figure is also NIH-wide, not HIV-specific.
#1 Best Overall
In its NIH funds decision, GAO concluded that “HHS violated the ICA when it withheld funds from obligation and expenditure.” GAO also noted HHS said the Federal Register publication pause had been lifted and NIH had caught up with its review pace compared with prior years. GAO said it would monitor ongoing litigation and could update its decision if relevant court findings emerged.
HIV-specific examples reported by House Oversight staff
A June 2026 report by Democratic staff of the House Committee on Oversight and Government Reform describes two distinct cases. These are HIV-specific examples, unlike GAO’s NIH-wide totals.
A canceled HIV vaccine research grant
The report says the administration canceled a $258 million grant spanning seven years for HIV vaccine research using neutralizing antibodies. It says the researchers had six months to wrap up the work. The amount and circumstances are claims made by the committee’s Democratic staff report.
Delayed HIV prevention funding in Los Angeles County
The same report says a $20 million HIV prevention grant for Los Angeles County was delayed as part of a nationwide freeze. It reports that the Centers for Disease Control and Prevention restored the funding on June 26, 2025, after advocacy and public pressure. According to the report and accounts from local providers, the delay led to canceled contracts, reduced services, or stopped care. This was prevention and service funding, not the same kind of NIH research award as the vaccine grant.
How the HIV funding picture compares with the examples
The NIH Office of AIDS Research (OAR) provides context for interpreting individual disruptions. OAR prepares HIV/AIDS research budget documents, allocates appropriated funds across NIH institutes and centers according to their research missions and the NIH strategic plan, and conducts an annual, multitiered review of supported grants, contracts, and intramural projects.
In its summary of the June 2026 advisory council meeting, OAR said, “Overall, NIH HIV funding has remained relatively stable” across FY 2019–2025. The summary also says funded-project counts fluctuated, application volumes rose while fewer awards were made, and the resulting competition increased despite larger average award sizes. It describes investment across areas including vaccines, reservoirs, epidemiology, mental health, implementation science, aging, co-occurring conditions, and workforce development. Stable overall funding over that period does not rule out disruptions to particular awards or delays in particular years.
Rank #4
A separate peer-review disruption followed the 2025 shutdown
The January–March notice pause was not the only interruption to NIH review. After the federal lapse in appropriations that began October 1, 2025, NIH said on November 24 that the shutdown had forced cancellation of more than 370 peer-review meetings, affecting more than 24,000 applications. NIH temporarily adjusted review practices to work through missed applications and adjusted Early Stage Investigator status for applicants affected by the delay. This was a separate episode from the earlier Federal Register publication pause.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
What the evidence does—and does not—establish
- It establishes documented disruption: GAO describes a period when NIH could not review and subsequently award grants as usual, while the House Oversight Democratic staff report gives HIV-specific examples of cancellation and delay.
- It does not provide a complete award inventory: the cited material does not establish the current grant-by-grant status of every HIV award affected by 2025 terminations or delays.
- It does not establish measured health outcomes caused by these actions: the available sources do not show a measured causal change in HIV infections or deaths attributable to the specific disruptions described here.
NIH funding status under the current continuing resolution
As of October 7, 2026, NIH says it is operating under the Continuing Appropriations and Extensions Act, 2027, signed September 2, 2026. NIH’s notice says funding continues through December 11, 2026, at the FY 2026 enacted level. It also says NIH institutes and centers may issue some non-competing awards below the latest Notice of Award level, with possible upward adjustments considered after FY 2027 appropriations. This is a time-limited funding status, not a grant-by-grant update on HIV awards.
Quick Recap
Best Value
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
